Table 3.
Association between BMI, VFA, SFA, AISI, SII, and overall survival
| Characteristic | Model I | Model II | Model III | Model IV | Model V | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI)1 | p value | HR (95% CI)1 | p value | HR (95% CI)1 | p value | HR (95% CI)1 | p value | HR (95% CI)1 | p value | |||
| BMI | ||||||||||||
| Underweight | 1.181 (0.356, 3.915) | 0.786 | 1.051 (0.312, 3.537) | 0.936 | 1.390 (0.419, 4.610) | 0.590 | 1.173 (0.353, 3.897) | 0.795 | ||||
| Normal | Ref | Ref | Ref | Ref | ||||||||
| Overweight | 0.836 (0.559, 1.252) | 0.385 | 0.979 (0.647, 1.481) | 0.920 | 0.716 (0.470, 1.090) | 0.119 | 0.831 (0.552, 1.252) | 0.376 | ||||
| Obese | 0.767 (0.495, 1.190) | 0.236 | 1.103 (0.696, 1.749) | 0.676 | 0.723 (0.465, 1.125) | 0.150 | 0.761 (0.486, 1.192) | 0.233 | ||||
| VFA | ||||||||||||
| High | Ref | Ref | Ref | Ref | ||||||||
| Low | 2.545 (1.785, 3.628) | < 0.001 | 2.601 (1.792, 3.776) | < 0.001 | 2.544 (1.783, 3.631) | < 0.001 | 3.193 (2.151, 4.739) | < 0.001 | ||||
| SFA | ||||||||||||
| High | Ref | Ref | Ref | Ref | ||||||||
| Low | 1.023 (0.719, 1.455) | 0.899 | 0.969 (0.674, 1.394) | 0.867 | 0.598 (0.403, 0.887) | 0.011 | 1.111 (0.778, 1.587) | 0.563 | ||||
| AISI | 1.235 (1.085, 1.406) | 0.001 | 1.274 (1.115, 1.456) | < 0.001 | 1.216 (1.067, 1.386) | 0.003 | 1.242 (1.090, 1.416) | 0.001 | ||||
| SII | 1.225 (1.060, 1.417) | 0.006 | 1.249 (1.081, 1.444) | 0.003 | 1.177 (1.014, 1.366) | 0.032 | 1.228 (1.062, 1.420) | 0.006 | ||||
Model II was adjusted for covariates plus BMI (underweight/normal/obese/overweight)
Model III was adjusted for covariates plus VFA (high/low)
Model IV was adjusted for covariates plus AISI (continuous) and SII (continuous)
Model V was adjusted for covariates plus SFA (high/low)
1HR hazard ratio, CI confidence interval, BMI body mass index, VFA visceral fat area, SFA subcutaneous fat area, AISI Aggregate Index of Systemic Inflammation, SII systemic immune- inflammation index
*All models were adjusted for the following covariates: age (continuous), gender (male/female), TMN stage (I/II), sarcopenia (with/ without)